Axsome Therapeutics Settles SUNOSI® ( solriamfetol ) Patent Litigation with Hetero Labs Ltd.
NEW YORK, May 27, 2025 ( GLOBE NEWSWIRE ) -- Axsome Therapeutics, Inc. ( NASDAQ: AXSM ) ( Axsome ) , a biopharmaceutical company leading a new era in the treatment of central nervous system ( CNS ) disorders, today announced that it has entered into a settlement agreement with Hetero Labs Ltd. ...
BioCryst to Present at Upcoming Investor Conferences - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., May 27, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that the company plans to present at the following conferences: Jefferies Global Healthcare Conference in New York on Wednesday, June 4, 2025, at 4:55 p.m. ET.
MEXC Announces the Listing of Sophon ( SOPH ) with $40,000 in SOPH and 50,000 USDT Prize Pool
VICTORIA, Seychelles, May 27, 2025 ( GLOBE NEWSWIRE ) -- MEXC, a leading global cryptocurrency exchange, will list Sophon ( SOPH ) on May 28, 2025 ( UTC ) .To celebrate the listing, MEXC is launching a special event for new and existing users, featuring a total prize pool of $40,000 in SOPH and ...
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® ( pemivibart ) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus
WALTHAM, Mass., May 27, 2025 ( GLOBE NEWSWIRE ) -- Invivyd, Inc. ( Nasdaq: IVVD ) today announced that results from its CANOPY Phase 3 clinical trial of pemivibart have been published online as an Advance Article in the peer-reviewed journal Clinical Infectious Diseases ( CID ) , available here.
Hong Kong's Gale Well suffers US$6.5 million loss on sale of 2 shops
Hong Kong property investment firm Gale Well Group, which has been divesting assets, sold three shops this month, incurring a loss of more than HK$51 million (US$6.5 million) on two of them, as the city's retail real estate market remains mired in a downturn.
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST-Modifier Gene Therapy for the Treatment of Stargardt Disease
MALVERN, Pa., May 27, 2025 ( GLOBE NEWSWIRE ) -- Ocugen, Inc. ( Ocugen or the Company ) ( NASDAQ: OCGN ) , a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the United States Food and Drug Administration ( U.S.
WeRide Stock Is Soaring Tuesday: What's Driving The Action? - WeRide ( NASDAQ:WRD )
WeRide stock jumps as it expands Robotaxi testing in Saudi cities, eyes full Uber rollout by late 2025. WeRide's Q1 Robotaxi revenue more than doubles as Middle East deployments boost commercial traction. Unlock your all-in-one trading dashboard with real-time alerts, rankings, and stock ...
British Monarchy Returns To Canadian Throne Speech Since 1977 As King Charles III Shows Solidarity Amid Trump's '51st State' Threats
In response to U.S. President Donald Trump's annexation threats, King Charles III is preparing to deliver a speech outlining the new government's priorities at the Canadian Parliament. What Happened: King Charles III's upcoming speech in the Canadian Parliament on Tuesday is a show of support for ...
Is Alphabet Stock Too Cheap to Ignore?
Sometimes, stocks fall to valuations where you can't pass them up. Most of the time, this occurs because of an overwhelming negative sentiment in the market, which tends to swing the pendulum too far in one direction.
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting - TG Therapeutics ( NASDAQ:TGTX )
NEW YORK, May 27, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. TGTX, today announced the upcoming schedule of presentations highlighting BRIUMVI® ( ublituximab-xiiy ) data in patients with relapsing forms of multiple sclerosis ( RMS ) , at the 2025 Consortium of Multiple Sclerosis Centers ( ...

